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Oxidized low-density lipoprotein (OxLDL) contributes to the atherosclerotic plaque formation and progression by several
mechanisms, including the induction of endothelial cell activation and dysfunction, macrophage foam cell formation, and smooth
muscle cell migration and proliferation. Vascular wall cells express on their surface several scavenger receptors that mediate the
cellular effects of OxLDL. The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the main OxLDL receptor of
endothelial cells, and it is expressed also inmacrophages and smoothmuscle cells. LOX-1 is almost undetectable under physiological
conditions, but it is upregulated following the exposure to several proinflammatory and proatherogenic stimuli and can be detected
in animal and human atherosclerotic lesions. The key contribution of LOX-1 to the atherogenic process has been confirmed in
animal models; LOX-1 knockout mice exhibit reduced intima thickness and inflammation and increased expression of protective
factors; on the contrary, LOX-1 overexpressing mice present an accelerated atherosclerotic lesion formation which is associated
with increased inflammation. In humans, LOX-1 gene polymorphisms were associated with increased susceptibility to myocardial
infarction. Inhibition of the LOX-1 receptor with chemicals or antisense nucleotides is currently being investigated and represents
an emerging approach for controlling OxLDL-LOX-1 mediated proatherogenic effects.
1. Introduction
1
2
Atherosclerosis is a chronic inflammatory vascular disease,
having as ultimate outcome the atheromatous plaque, a
focal lesion located within the intima of large and medium
sized arteries [1, 2]. Subendothelial retention of low den-
sity lipoprotein (LDL) and its oxidative modification rep-
resent the initial event in atherogenesis, which is followed
by infiltration and activation of blood inflammatory cells.
Oxidized LDL (OxLDL) in fact activates endothelial cells
(ECs) by inducing the expression of several cell surface
adhesion molecules which mediate the rolling and adhesion
of blood leukocytes (monocytes and T cells); after adhesion
to the endothelium, leukocytes migrate into the intima in
response to chemokines. Monocytes then differentiate into
macrophages that upregulate both toll-like receptors (TLRs),
involved in macrophage activation, and scavenger receptors
(SRs), that internalize apoptotic cell fragments, bacterial
endotoxins, and OxLDL, leading to lipid accumulation and
foam cell formation [2]. Macrophage activation leads to the
release of proinflammatory cytokines, reactive oxygen species
(ROS), proteolytic enzymes involved in matrix degradation
and thus in atherosclerotic plaque destabilization. T cells
respond to local peptide antigens present on the surface
of antigen-presenting cells, become activated, and release
proinflammatory cytokines [2]. 3
OxLDL acts via binding to several SRs, including SR-A,
SR-BI, CD36, and lectin-like oxidized low-density lipopro-
tein receptor-1 (LOX-1) [3]. LOX-1 is a type II integral mem-
brane glycoprotein consisting of a short N-terminal cyto-
plasmic domain, a transmembrane domain, a neck region,
which regulates receptor oligomerization, and an extracel-
lular C-type lectin-like extracellular domain, involved in
ligand binding (Figure 1) [4]. LOX-1 has been identified
first in ECs as the major OxLDL receptor [5]; however
also macrophages and smooth muscle cells express LOX-1
2 Mediators of Inflammation
Table 1: LOX-1 inducers.
Proinflammatory cytokines
Tumor necrosis factor 𝛼 (TNF𝛼)
Interleukin-1 (IL-1)
Interferon 𝛾 (IFN𝛾)
Lipopolysaccharide (LPS)
C-reactive protein (CRP)
Modified lipoproteins
OxLDL (copper-oxidized LDL)
15-Lipoxygenase-modified LDL
15-Lipoxygenase-modified HDL3
Glycoxidized-LDL
Lysophosphatidylcholine (LPC)
Palmitic acid
Hypertension-related stimuli
Angiotensin II
Endothelin-1
Fluid shear stress
Hyperglycemic stimuli
High glucose
Advanced glycation end-products (AGEs)
Other stimuli
Homocysteine
Free radicals
together with other SRs [6]. Basal cellular LOX-1 expression
is very low, but it can be induced by several proinflammatory
and proatherogenic stimuli [7, 8]. In vitro, LOX-1 expres-
sion is induced by many stimuli related to atherosclerosis,
including proinflammatory cytokines such as tumor necrosis
factor alpha (TNF𝛼), interleukin-1 (IL-1), and interferon-
gamma (IFN𝛾); angiotensin II; endothelin-1; OxLDL and
other modified lipoproteins; free radicals; and fluid shear
stress [8–10] (Table 1). In vivo, the expression of LOX-14
is upregulated in the presence of pathological conditions
including atherosclerosis, hypertension, and diabetes [8]
(Figure 2). In human atherosclerotic lesions, LOX-1 is over-5
expressed in ECs especially in the early stage of atherogenesis;
in advanced atherosclerotic plaques, LOX-1 is overexpressed
in ECs of neovascular formations [11]. Furthermore, LOX-1 is
highly expressed by intimal smooth muscle cells (SMCs) and
macrophages in human carotid atherosclerotic plaques [11],
suggesting the roles for LOX-1 in endothelial activation and
in foam cell formation. Finally, the results obtained in LOX-
1 knockout or LOX-1 overexpressing mice have suggested a
key contribution of LOX-1 in the inflammatory response and
lipid deposition in heart vessels [12, 13].
Besides OxLDL, LOX-1 binds multiple ligands, including
other forms of modified lipoproteins, advanced glycation
end-products, activated platelets, and apoptotic cells [8–10]
(Table 2). LOX-1 also binds delipidated OxLDL, suggesting
Table 2: LOX-1 ligands.
Modified lipoproteins Other ligands
OxLDL (copper-oxidized LDL) Apoptotic cells
15-Lipoxygenase-oxidized LDL Activated platelets
15-Lipoxygenase-oxidized HDL3
Advanced glycation
end-products (AGEs)
Glycoxidized LDL
Delipidated OxLDL
HOCl-modified HDL
that LOX-1 recognizes the modified apolipoprotein B; fur-
thermore, LOX-1 binds with higher affinity tomildly oxidized
LDL rather than extensively oxidized LDL, suggesting the
ability to recognize also oxidized lipids (i.e., lipids that are
covalently bound to the protein and are not removed by
the delipidation process) [3] (Table 2). OxLDL is rapidly
internalized into cells following the interaction with LOX-
1; this internalization process is inhibited by LOX-1-blocking
antibody which acts by preventing the binding of OxLDL
with the receptor [14]. After the endocytosis of the complex
OxLDL-LOX-1, the receptor is uncoupled from OxLDL, and
both are located in separate compartments within the cytosol
[14].
LOX-1 is mainly localized in caveolae/lipid rafts
(cholesterol-enriched membrane microdomains) in the
plasma membrane; its function is modulated by the
cholesterol content of membrane: cholesterol depletion
induces the mislocalization of LOX-1, which results in a
more diffuse distribution of the receptor in the plasma
membrane (without a reduction of the amount of receptor
exposed on the cell surface) and in a marked reduction
of LOX-1-mediated OxLDL binding and uptake [15]. This
finding suggests that the clustered distribution of LOX-1
in specific membrane microdomains is essential for an
efficient interaction with OxLDL and for the internalization
of OxLDL-LOX-1 complexes.
2. LOX-1-Mediated Endothelial Dysfunction
2.1. LOX-1 Upregulation by OxLDL. Endothelial dysfunction
represents a very early stage in the atherogenic process
and is a pathological condition characterized by alterations
in anti-inflammatory and anticoagulant properties and by
impaired ability to regulate vascular tone. LOX-1 is the main
receptor for OxLDL in ECs [5], and OxLDL, through LOX-
1, contributes to the induction of endothelial dysfunction
by several mechanisms (Figure 3). Basal LOX-1 expression is
very low, but it can be induced by proinflammatory cytokines
generated in a local environmentwithin the arterial wall or by
other atherogenic stimuli including OxLDL [8].
OxLDL upregulates LOX-1 mRNA and protein expres-
sion in a dose-dependent manner [16]; OxLDL-mediated
upregulation of LOX-1 is suppressed by pretreatment of cells
with antisense to LOX-1 mRNA [17], suggesting that OxLDL
modulates its own receptor through interaction with LOX-
1. In vitro, LOX-1 expression can be upregulated in ECs also
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Figure 1: Schematic representation of LOX-1 structure. LOX-1 consists of four domains: a cytoplasmic N-terminal domain, a single
transmembrane domain, an extracellular neck domain, and an extracellular lectin-like domain.
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Figure 2: In vivo stimuli of LOX-1. Several pathological conditions can upregulate LOX-1 expression resulting in vascular wall cell activation.
by 15-lipoxygenase-modified LDL, andLOX-1 overexpression
increases the association of 15-lipoxygenase-modified LDL
to ECs [9], supporting the hypothesis that also minimally
oxidized LDL may contribute to LOX-1 induction and to EC
activation. LOX-1 upregulation occurs also in ECs exposed to
15-lipoxygenase-modified HDL
3
; this modified lipoprotein is
also a ligand for LOX-1 [10].
2.2. LOX-1 Mediates OxLDL-Induced EC Activation. After
adhesion to the endothelium, monocytes migrate into the
intima where they differentiate into macrophages, accumu-
late lipids, and become foam cells. Recruitment of monocytes
involves both chemokines and adhesion molecules. Mono-
cyte chemoattractant protein-1 (MCP-1) is a chemotactic
protein formonocytes; incubation of ECswithOxLDL signif-
icantly increases MCP-1 expression and monocyte adhesion
to ECs; these effects are both suppressed in the presence of
an antisense to LOX-1 mRNA [18]. Activation of mitogen-
activated protein kinase (MAPK) is required for OxLDL-
mediated induction ofMCP-1, and antisense to LOX-1mRNA
completely inhibits the OxLDL-induced MAPK activation
[18]. Additional chemokines are upregulated by LOX-1 acti-
vation in response to OxLDL, including IL-8, chemokine (C-
X-C motif) ligands 2 and 3 (CXCL2 and CXCL3) [19].
Upregulation of endothelial adhesion molecules con-
tributes to the leukocyte adhesion; OxLDL significantly
increases the expression of E-selectin, P-selectin, vascular cell
adhesion molecule-1 (VCAM-1), and intercellular adhesion
molecule-1 (ICAM-1) in ECs [20]. These effects are mediated
by LOX-1, since antisense to LOX-1 mRNA decreases both
LOX-1 expression and adhesion molecule upregulation in
response to OxLDL [20]. In addition, pretreatment of ECs
with a statin or with polyinosinic acid or carrageenan (two
known ligands of LOX-1) lowers OxLDL-induced expression
of LOX-1 as well as adhesion molecules, confirming that
LOX-1 activation plays an important role in OxLDL-induced
expression of adhesion molecules [20, 21]. ICAM-1 expres-
sion is upregulated in LOX-1-overexpressing ECs exposed
to 15-lipoxygenase-modified LDL [9], providing a role for
minimally modified LDL (mmLDL) as proinflammatory
particle.
Nuclear factor kappa B (NF-𝜅B), which is activated by
several proinflammatory cytokines,modulates the expression
of proinflammatory genes, including adhesion molecules,
cytokines, and chemokines, and is also involved in LOX-
1 upregulation [8, 22]. OxLDL, following the binding with
LOX-1, activates NF-𝜅B; preincubation of ECs with anti-
LOX-1 antibody markedly attenuates the transcription factor
activation [23]. 6
The stimulation of CD40/CD40L signaling results in the
induction of proatherogenic pathways (including the expres-
sion of adhesion molecules and proinflammatory cytokines)
and in EC activation [24]. Incubation of human coronary
artery endothelial cells (HCAECs) with OxLDL increases the
expression of CD40 andCD40L, while the inhibition of LOX-
1 with a blocking antibody reduces the OxLDL-mediated
increase of CD40 [25].
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Figure 3: Role of LOX-1 in atherosclerosis.OxLDLbinding to LOX-1 induces endothelial activation anddysfunction, supports the recruitment
of circulating leukocytes, triggers foam cell formation, and sustains migration and proliferation of smooth muscle cells, thus contributing to
the development of the atherosclerotic plaque. Furthermore, OxLDL-LOX-1 interaction may also contribute to plaque destabilization by
inducing smooth muscle cell apoptosis and the release of matrix degrading enzymes (MMPs).
2.3. OxLDL-LOX-1 Interaction Impairs Endothelium-
Dependent Relaxation. ECs, due to their location at the
interface between blood and the vessel wall, play a crucial
role in the control of vascular tone and homeostasis, through
the production of several vasoactive mediators. Among
them, nitric oxide (NO) is produced by endothelial NO
synthase (eNOS) in response to several stimuli; functions
mainly as a vasodilator; inhibits leukocyte-endothelial cell
adhesion, platelet adhesion and aggregation, and smooth
muscle cell proliferation; and stimulates angiogenesis [26]. In
disease conditions, ECs exhibit a reduced NO bioavailability,
due to an increased degradation of NO in response to
an enhanced oxidative stress [26]. The release of NO by
ECs can be reduced by OxLDL:OxLDL displaces eNOS
from its caveolae membrane localization by depleting
caveolae of cholesterol, thus inhibiting NO generation [27].
Furthermore, OxLDL inactivates NO through an oxidative
mechanism by increasing cellular production of reactive
oxygen species (ROS), and in particular superoxide [28].
Anti-LOX-1 monoclonal antibody reduces superoxide
formation and increases intracellular NO level, suggesting
the involvement of LOX-1 in these OxLDL-induced effects
[28]. Additionally, OxLDL activates endothelial arginase
II (which regulates NO production by competing with
eNOS for the common substrate L-arginine) through the
dissociation of arginase from the microtubule cytoskeleton,
resulting in a decreased NO production and a raise of ROS
[29, 30]. The increased arginase activity is inhibited by
monoclonal antibody to LOX-1; furthermore, ECs from
LOX-1 knockout (KO) mice do not increase arginase
activity and exhibit reduced changes in NO and superoxide
production in response to OxLDL [30], thus confirming
the involvement of LOX-1 in OxLDL-mediated arginase
activity. Further, neutralizing antibodies to LOX-1 restore
NO-mediated coronary arteriolar dilation in ApoE KO mice
[31].
Dysfunctional ECs can also generate vasoconstrictor
factors, including endothelin-1 (ET-1) and angiotensin II
(Ang II). ET-1 is a potent vasoconstrictor, proinflammatory,
and mitogenic peptide produced by injured vascular ECs in
response to several stimuli; a tight interaction exists between
ET-1 and OxLDL: OxLDL stimulates the generation of ET-
1, and ET-1 enhances the uptake of OxLDL in ECs by
promoting the expression of LOX-1 [32]. Incubation of ECs
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with OxLDL increases ET-1 mRNA and protein expression,
an effect inhibited by anti-LOX-1 antibody [33].
Renin-angiotensin systemmay contribute to the endothe-
lial dysfunction; angiotensin-converting enzyme (ACE),
which converts Ang I to Ang II, is mainly expressed in ECs
[34]. Ang II induces LOX-1 expression and facilitates OxLDL
uptake by ECs [35]; in turn, OxLDL increases the expression
of ACE in a concentration- and time-dependent manner.
The upregulation of ACE expression in response to OxLDL
is mediated by LOX-1, as pretreatment of ECs with LOX-1-
blocking antibody significantly reduces the OxLDL-induced
expression of ACE [36].
2.4. LOX-1 Mediates OxLDL-Induced Apoptosis of ECs. Incu-
bation with high concentrations of OxLDL induces cellular
changes thatmay result in cell death.OxLDLmay induce both
necrosis and apoptosis; the last is a highly regulated process
and involves multiple pathways, including ROS generation,
caspase and protein kinase activation, alteration of calcium
homeostasis, and alteration of proapoptotic/antiapoptotic
gene expression [37]. EC apoptosis results in increased
vascular permeability to cells and lipids, smooth muscle cell
proliferation, and increased coagulation, thus contributing to
the development of atherosclerotic lesions.
OxLDL induces EC apoptosis through LOX-1; in fact,
inhibition with antisense to LOX-1 mRNA or with chemical
inhibitors of LOX-1 significantly reduces the number of
apoptotic cells in response to OxLDL [17]. NF-𝜅B activation
following EC exposure toOxLDL acts as a signal transduction
mechanism in LOX-1-mediated apoptosis, and antisense to
LOX-1 significantly inhibits OxLDL-induced NF-𝜅B activa-
tion [17].
OxLDL also activates caspase-9 and caspase-3 in ECs and
induces the release of mitochondrial activators of caspases,
while reducing the expression of the antiapoptotic proteins
B-cell lymphoma 2 (Bcl-2) and cellular inhibitor of apoptosis
protein 1 (c-IAP-1) [38]. These effects are mediated by LOX-
1, as pretreatment of cells with antisense to LOX-1 mRNA
significantly decreasesOxLDL-induced activation of caspases
as well as the percentage of apoptotic cells [38].These findings
indicate that OxLDL through its receptor LOX-1 modulates
activity and expression of relevant players in apoptosis.
Fas is a death-receptor that triggers apoptosis when
activated by its ligand FasL and is involved in OxLDL-
induced apoptosis; in fact, OxLDL sensitizes vascular cells
to Fas-mediated apoptosis, upregulating Fas surface expres-
sion, while OxLDL-induced apoptosis is reduced by FasL-
neutralizing antibodies [37]. LOX-1 activation is involved
in these effects, as neutralizing LOX-1 antibody prevents
OxLDL-induced activation of Fas-mediated apoptosis and
inhibits OxLDL-induced modulation of surface Fas expres-
sion in ECs [39].
2.5. OxLDL Increases Oxidative Stress through LOX-1 in ECs.
High levels of ROS are produced in several disease conditions,
including atherosclerosis, and contribute to endothelial dys-
function. ROS are involved in LDL oxidation, and, in turn,
OxLDL mediates many of its biological effects by generating
more intracellular ROS through the binding to LOX-1; anti-
LOX-1 antibody markedly reduces OxLDL-induced ROS
formation [23, 40]. OxLDL-induced increase of ROS also
results in NF-𝜅B activation [23] and in EC apoptosis [40];
both these effects are mediated by LOX-1, as pretreatment of
the cells with LOX-1-blocking antibody significantly reduces
ROS production, NF-𝜅B activation, and apoptosis rate in
response to OxLDL [23, 40].
Endothelial NADPH oxidase, a multisubunit enzymatic
complex, is a major source of ROS in vascular ECs, and
OxLDL induces a significant increase of NADPH oxidase-
generated ROS in ECs [41]. The binding of OxLDL to LOX-
1 activates NADPH oxidase by inducing translocation of
specific subunits on the cell membrane, leading to a rapid
increase in intracellular ROS such as hydrogen peroxide and
superoxide; the latter reacts with intracellular NO, thereby
causes intracellular NO level to decrease, and upregulates
LOX-1 expression, thus resulting in further increase in ROS
production [42].
p66Shc is a redox enzyme involved in mitochondrial
ROS generation and the translation of oxidative signals into
apoptosis; higher levels of p66Shc have been found under
pathological conditions and well correlated with oxidative
stress in cardiovascular disease [43]. When exposed to
OxLDL, ECs increase phosphorylation of p66Shc, an effect
that is prevented by blockade or molecular silencing of LOX-
1 [43], supporting a role for LOX-1 also in this OxLDL-
mediated effect. On the other hand, lysophosphatidylcholine
(LPC), a relevant component of OxLDL, induced p66Shc
activation independently of LOX-1 [43].
In HCAECs, OxLDL promotes intracellular ROS pro-
duction and induces DNA oxidative damage [44], resulting
in the regulation of several transcription factors, including
NF-𝜅B and octamer-binding transcription factor-1 (Oct-
1). Oct-1 acts as a transcriptional repressor for endothelial
enzymes involved in the production of vasoactive molecules,
thus providing a link between oxidative DNA damage and
impaired function of endothelium upon exposure to OxLDL.
Oct-1 is also involved in OxLDL-induced LOX-1 promoter
activation and gene expression [45]. Inhibition of LOX-
1 attenuates OxLDL-mediated endothelial DNA damage,
Oct-1/DNA binding, and reverses impaired production of
vasoactive compound [44].
2.6. Other Effects of OxLDL Mediated by LOX-1 in ECs.
Incubation of ECs with OxLDL modulates the expression of
several other genes associated with atherosclerosis, and LOX-
1 plays a crucial role in mediating such effects.
Metalloproteinases (MMPs) are a family of matrix
degrading enzymes involved in vascular remodeling that con-
tribute to the determination of atherosclerotic plaque stabil-
ity; their expression and activity are increased in atheroscle-
rotic plaques [46]. OxLDL increases the expression of MMP-
1 and MMP-3 mRNA and protein in ECs, without affect-
ing the expression of tissue inhibitor of metalloproteinases
(TIMPs) [47], suggesting an OxLDL-induced imbalance
between MMPs and TIMPs. LOX-1 activation mediates the
modulation of MMPs by OxLDL: LOX-1-blocking antibody
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prevents the increase of MMPs in response to OxLDL [47].
Similarly, OxLDL enhances MMP-9 production in human
aortic ECs, and anti-LOX-1 antibody inhibits this effect [48].
Angiogenesis is a highly regulated physiological pro-
cess involved in several pathological conditions including
inflammation and atherosclerosis and requires disruption of
cell-cell contact, EC migration, proliferation, and capillary
tube formation. Generation of small amount of ROS, as
those induced by low concentrations of OxLDL (<5 𝜇g/mL),
seems to be involved in this process. Low concentrations
of OxLDL stimulate tube formation from ECs in vitro. This
effect is inhibited by anti-LOX-1 antibody, that also decreases
OxLDL-induced ROS generation, NF-𝜅B activation, and
upregulation of vascular endothelial growth factor (VEGF)
[49].
The plasminogen activator (PA) is involved in the con-
trol of fibrinolysis within the vascular lumen; plasminogen
activator inhibitor-1 (PAI-1) attenuates fibrinolysis through
inhibition of plasminogen activation and modulates cellular
responses; increased expression of PAI-1 has been described
in atherosclerosis [50]. OxLDL induces PAI-1 upregulation
in cultured ECs through LOX-1, as showen by the inhibitory
effect of anti-LOX-1-blocking antibody; this finding suggests
an involvement of LOX-1 also in OxLDL-induced thrombotic
process [51].
The LDL receptor regulates plasma LDL-cholesterol lev-
els. OxLDL decreases the expression of LDL receptor in
a concentration- and time-dependent manner in HCAECs
[52]. This effect is mediated by LOX-1, as cell pretreatment
with LOX-1-blocking antibody or with antisense to LOX-
1 mRNA reduces the effect of OxLDL on LDL-receptor
expression [52].
2.7. LOX-1 Mediates OxLDL-Induced Effects in Endothelial
Progenitor Cells. Endothelial progenitor cells (EPCs) are
involved in the regeneration of the injured endothelium and
in the neovascularization process, which represents a com-
pensatory mechanism in ischemic disease; atherosclerosis is
associated with reduced numbers and impaired functionality
of EPCs [53]. OxLDL has a negative effect on EPCs, induces
EPC senescence, inhibits VEGF-induced EPCdifferentiation,
decreases EPC number, and impairs their function [54–
56]. LOX-1 is expressed in EPCs, and incubation of EPCs
with OxLDL increases LOX-1 expression [57], an effect
depending on the interaction between OxLDL and LOX-1,
as confirmed by the use of an anti-LOX-1 antibody. OxLDL
also induces EPC apoptosis in a dose-dependent manner,
thus reducing their survival; moreover, OxLDL impairs EPC
adhesive, migratory, and tube formation capacities [57]. All
these effects are attenuated by pretreatment with a LOX-1
monoclonal antibody. Furthermore, OxLDL reduces eNOS
expression and NO production, that may in part explain the
inhibitory effect of OxLDL on EPC survival and function
[57]. Pretreatmentwith anti-LOX-1 antibody inhibits all these
OxLDL-induced effects.
At low concentrations (<10 𝜇g/mL) OxLDL does not
induce apoptosis but accelerates EPC senescence; this effect
is significantly attenuated by LOX-1-blocking antibody or by
atorvastatin (that reduces LOX-1 expression) [54]. OxLDL
significantly reduces telomerase activity (which plays a criti-
cal role in cellular senescence) and impairs proliferation and
network formation capacity, resulting in cellular dysfunction
[54].
3. Role of LOX-1 in OxLDL-Induced Smooth
Muscle Cell Proliferation and Apoptosis
LOX-1 is expressed also in smooth muscle cells (SMCs) [6];
in vitro, several stimuli, including OxLDL and Ang II, can
upregulate LOX-1 expression in SMCs [58–60]; in vivo, LOX-
1 protein is not detectable in the media of noninjured aorta
but is present in SMCs two days after vascular injury or after
balloon-angioplasty [61]. OxLDL and LOX-1 colocalize with
SMCs of human restenotic lesions, suggesting a role for LOX-
1 in OxLDL-induced SMC proliferation and restenosis [61].
MicroRNAs are small noncoding RNAs that negatively
modulate gene expression through the binding with their
mRNAand play a role also in atherosclerosis [60].MicroRNA
let-7g targets LOX-1 gene and inhibits its expression; OxLDL,
by inducing the transcription factor Oct-1, reduces let-7g
expression. Let-7g mimic reduces OxLDL-induced LOX-1
and Oct-1 upregulation as well as OxLDL-enhanced SMC
proliferation and migration [60].
At higher concentrations, OxLDL upregulates LOX-1
expression and induces apoptosis of vascular SMCs [62]
(Figure 3), a process that may contribute to atherosclerotic
plaque destabilization. OxLDL-induced apoptosis is a con-
sequence of LOX-1 upregulation, as apoptosis is inhibited
by a neutralizing anti-LOX-1 antibody. Furthermore, OxLDL
increases the expression of the proapoptotic protein Bcl-2-
associated X protein (Bax) and inhibits the expression of
the antiapoptotic Bcl2. This effect is mediated by LOX-1,
as anti-LOX-1 antibody markedly inhibits OxLDL-induced
modulation of these two proteins [62]. LOX-1 colocalizes
with Bax in human atherosclerotic plaques, particularly in
rupture-prone shoulder region, suggesting a role for LOX-1
in the mechanisms that contribute to plaque destabilization
[62].
Since SMCs can transform into foam cells, LOX-1 might
be a potential player in this process (Figure 3). Treatment
of SMCs with LPC increases LOX-1 expression [63], with
consequent LOX-1-mediated increase of OxLDL uptake;
anti-LOX-1 antibody markedly inhibits the LPC-enhanced
OxLDL uptake [63].
Bone marrow cells can potentially originate smooth
muscle progenitor cells (SMPCs) that may differentiate into
smooth muscle-like cells (SMLCs) in the damaged ves-
sels [64], thus contributing to the atherogenic process. In
vitro, long-term culture with platelet-derived growth factor
PDGF-BB induces the differentiation of SMPCs into SMLCs
that express SMC-specific markers [65]; OxLDL inhibits
PDGF-BB-induced differentiation of SMLCs, as revealed by
the decrease of SMC marker expression in the presence
of OxLDL. Furthermore, OxLDL incubation induces lipid
droplet accumulation in the cytoplasm and LOX-1 surface
expression [65]. Anti-LOX-1 antibody significantly reduces
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OxLDL uptake by SMLCs, suggesting a role for LOX-1 in the
transdifferentiation of SMLCs into foam-like cells [65].
4. Role of LOX-1 in OxLDL-Induced Effects in
Macrophages
Macrophages internalize OxLDL by several SRs including
SR-AI/II, SR-BI, cluster of differentiation 36 (CD36), and
LOX-1, resulting in lipid accumulation and transformation
into foam cells. LOX-1 is not detectable in freshly isolated
human monocytes, but its expression increases in differen-
tiated macrophages [66]. LOX-1 expression in macrophages
can be upregulated by several stimuli, including OxLDL,
LPC, high-glucose levels, and proinflammatory cytokines
[8]. The contribution of LOX-1 in macrophage uptake and
degradation of OxLDL under normal conditions is small. No
significant differences are observed between wild-type and
LOX-1 deficient macrophages [67], probably due to the high
expression of other SRs that could mask the contribution of
LOX-1. However, in cells stimulated with LPC, LOX-1 expres-
sion andOxLDL uptake and degradation increase in wilt type
cells but not in LOX-1-deficient cells [67].These observations
suggest that LOX-1 gene inactivation does notmarkedlymod-
ify OxLDL uptake in unstimulated macrophages, as LOX-1
accounts for 5–10%ofOxLDLuptake by these cells, but, when
LOX-1 is upregulated, internalization of OxLDL increases by
more than 40% [67] (Figure 2). Proinflammatory cytokines
upregulate LOX-1 and downregulate other SRs (SR-AI/II
and CD36), suggesting that, in inflamedmicroenvironments,
where these cytokines are relatively abundant (such as in
atherosclerotic lesions), LOX-1 might play a significant role
in macrophage OxLDL uptake.
Monocytes may also differentiate into dendritic cells
(DCs), a specific type of leukocytes that play a key role
in the initiation of innate and adaptive immune responses,
and OxLDL affects both DC maturation and migration
[68, 69]. LOX-1 is highly expressed on mature DCs and
significantly contributes to OxLDL uptake, as anti-LOX-1
antibody reduced OxLDL uptake by 48% [70].
5. Role of LOX-1 in Platelet Activation
Platelets express several SRs, some of which are constitu-
tively expressed (including CD36), while LOX-1 appears on
the surface of platelets on activation [71]; thus, in resting
platelets, CD36 mediates OxLDL binding to platelets, while,
in activated platelets, in which OxLDL binding is increased
compared to resting cells, binding of OxLDL is mediated by
both CD36 and LOX-1 [71]. Activated platelets internalize
significant amount of OxLDL compared with resting platelets
[72] (Figure 3); OxLDL induces platelet activation, increases
their ability to adhere to ECs, induces an inflammatory
response, and leads to platelet accumulation after vascular
injury. In fact, OxLDL-positive platelets induce adhesion
molecule expression on ECs, reduce regeneration of ECs,
and induce foam cell formation [72], suggesting that OxLDL-
activated platelets may contribute to vascular inflammation
by several mechanisms.
Dysfunctional endothelium exhibits procoagulant and
adhesive properties to platelets, and endothelial LOX-1 plays
a major role in the platelet-endothelium interaction thus
enhancing endothelial dysfunction. In fact LOX-1 binds also
anionic phospholipids, including those present on the surface
of apoptotic cells or activated platelets [73], thus working as
an adhesion molecule for platelets. OxLDL partially inhibits
the binding of platelets to LOX-1, indicating a high affinity
of platelets for this receptor [73]. The binding of activated
platelets to endothelial LOX-1 induces the release of ET-
1, further supporting the induction of endothelial dysfunc-
tion [73]. Furthermore, the binding of activated platelet to
endothelial LOX-1 induces ROS generation followed by a
reduction of NO bioavailability; all effects are prevented by
anti-LOX-1 antibody [74].
6. LOX-1 and Atherosclerosis: Experimental
Evidences
As previously described, LOX-1 mediates many of the effects
of OxLDL, that is, EC growth, dysfunction, adhesion, and
activation of monocytes/macrophages, and all critical fea-
tures of atherosclerosis. LOX-1 mRNA has also been found
in human atherosclerotic plaques, while negligible amounts
are detectable in unaffected aortas [11]. The key relevance
of LOX-1 in atherosclerosis has been demonstrated by key
experiments in LOX-1 KO mice crossed to a mouse model
prone to develop atherosclerosis such as the LDL-R KO
mouse. Feeding thesemice with a cholesterol-rich diet results
in a reduced binding of OxLDL to the aortic endothelium
and a preservation of endothelium-dependent vasorelaxation
after treatment with OxLDL compared to wild type animals
[12]. More importantly, LOX-1 KO/LDL-R KO animals show
a significant reduction in atherosclerosis compared with
LDL-R KO mice [12]. This is associated with reduced NF-
𝜅B expression as well as decreased inflammatory markers
and also with an increased eNOS expression, suggesting an
improved endothelial function [12]. Conversely, mice over-
expressing LOX-1 on ApoE KO background show a dramatic
increase in atherosclerosis compared to the nontransgenic
mice [13]. In hypercholesterolemic rabbits, LOX-1 expression
is detected mainly in atherosclerotic plaques with a thinner
fibromuscular cap and is localized to the lipid core where it
correlates with tissue factor expression and apoptosis [75],
potentially connecting LOX-1 with plaque destabilization and
rupture. In line with this, LOX-1 expression is increased in
unstable plaques when the AMI-prone Watanabe heritable
hyperlipidemic rabbit and control rabbits are injected with an
antibody tracing LOX-1 [76].
Among the critical player in atherogenesis, the activation
of the rennin-angiotensin system and the consequent gener-
ation of Ang II are thought to be critical factors. Ang II via its
type 1 receptor (AT1 receptor) also upregulates the expression
of LOX-1 mRNA, and OxLDL via LOX-1 upregulates the
expression of AT1 receptor [77]. Of note hypertensive rats
present an upregulation of LOX-1 expressionmainly in vascu-
lar ECs [78–80]. The mutually facilitatory cross-talk between
LOX-1 and AT1 receptors may explain the coexistence of
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multiple risk factors in the same patient and the increase
in atherosclerosis risk with the presence of multiple risk
factors. In agreement with this assumption, LOX-1 expression
is increased in several animal models of cardiometabolic
disorders, including streptozotocin-induced diabetes [81] or
ischemia-reperfusion (I/R) injury [82]. LOX-1 deficiency is
associated with a more preserved left ventricular function
following I/R injury which resulted in a reduced oxidative
stress, collagen deposition, and fibronectin expression thus
resulting in a significant decrease inmyocardial injury as well
as in the accumulation of inflammatory cells [83, 84].
Altogether, the results from experimental atherosclerosis
support a proatherogenic role for LOX-1.
7. Genetics of LOX-1 and Atherosclerosis
LOX-1 is encoded by the oxidized low-density lipoprotein
(lectin-like) receptor 1 (OLR1) gene, mapped to chromosome
12p13 [85]. The association of polymorphisms in the human
OLR1 gene with the susceptibility to myocardial infarction
(MI) has been reported [85, 86]. In particular, six single
nucleotide polymorphisms (SNPs), located within introns 4,
5, and 3󸀠 UTR (untranslated region), that are comprised in
a linkage disequilibrium (LD) block are strongly associated
with the elevated risk to develop MI [86]. The observation
that the SNPs related to an increased risk of MI do not
affect the coding sequence of the gene suggests the possibility
that the SNPs could give rise to a functional product such
as messenger RNA (mRNA) isoforms as a consequence of
alternative splicing. Indeed it has been shown that the SNPs
located in the LD block regulate the level of the new fully
functional transcript bymodulating the retention of exon 5 of
the OLR1 gene [85]. The alternative splicing of OLR1 mRNA
leads to different ratios of LOX-1 full receptor and LOXIN
(lack of exon 5), an isoform lacking part of the C-terminus
lectin-like domain which is a functional domain. LOXIN,
through heterooligomerization with LOX-1 [87], blocks the
negative effects of LOX-1 activation, and this variant has a
functional role on plaque instability and therefore in the
pathogenesis of MI [86]. Ex vivo data show that macrophages
from subjects carrying the “nonrisk” allele at OLR1 gene dis-
play increased expression of LOXIN resulting in protection
against OxLDL-mediated apoptosis [87].
Later, an SNP on exon 4, rs11053646 (G501C), which
leads to an amino acidic substitution (lysine to asparagine at
position 167, K167N) has been studied. Of note, basic residues
in the lectin domain are important for strengthening the
ligand binding; substitution of this residue (K167N) causes a
change on the positive isopotential surface and thereby results
in reduced binding and internalization of OxLDL [88]. This
study, performed on CV-1 (simian) in Origin and carrying
the SV40 (COS-1) cells overexpressing either GG (KK) or CC
(NN) LOX-1, showed that GG (KK) COS-1 cells bind and
internalize less OxLDL than CC (NN) [88].
The K167N SNP has been identified among others in the
ORL-1 gene to be associated with acute MI and coronary
artery disease (CAD) [89–91]. The frequencies of the KK
genotype and the K allele are higher in the CAD group than
in controls (𝑃 < 0.05), while the opposite is true for NN
genotype (𝑃 < 0.05) [92]. The relevance of LOX-1 SNPs
has been tested also in relation to markers of atherosclerosis.
Among them, ultrasound detection and quantification of the
common carotid artery wall thickness (intima-media thick-
ness, IMT) are considered a surrogate marker of subclinical
atherosclerosis [93, 94]. The association between the non-
synonymous substitution K167N (rs11053646) and IMT has
been tested in 2,141 samples from the Progression of Lesions
in the Intima of the Carotid (PLIC) study (a prospective
population-based study) [95]. Significantly increased IMT
has been observed in male carriers of the minor C (N) allele
compared to GC and GG (KN and KK) genotypes [95]. A
gender-specific association has been also described between
the C (N) allele and prevalence of carotid plaque also in a
cohort of Dominican-Hispanic origin [96].
Functional analysis onmacrophages suggests a decreased
association to OxLDL in NN carriers compared to KN
and KK carriers which is also associated with a reduced
OLR1mRNAexpression [95].Macrophages fromNNcarriers
present also a specific inflammatory gene expression pattern
compared to cells from KN and KK carriers [95]. How these
data, obtained with human primarymacrophages, relate with
those obtained in a transfected fibroblast-like cell line derived
frommonkey kidney tissue is unclear, and further studies are
warranted to clarify this issue [88].
In summary, genetic alterations favoring LOXIN isoform
production coupled to the observation that this isoform
exerts a dominant-negative effect on LOX-1 function make it
an attractive new target for prevention and treatment of ini-
tiation, progression, and clinical consequences of atheroscle-
rosis such as plaque instability, acute myocardial infarction,
and ischemia reperfusion injury.
8. Concluding Remarks
OxLDL plays multiple roles in atherosclerosis; LOX-1 scav-
enger receptor mediates many of the OxLDL-induced effects,
and the OxLDL-LOX-1 interaction can alter the expression of
several genes, resulting in the induction of cellular dysfunc-
tion, proliferation, and apoptosis. A recent study showed that
LOX-1 inhibition in ApoE KO mice using a schizophyllan-
based antisense oligonucleotide therapy resulted in reduced
LOX-1 expression in the arterial wall [97]. Blocking the
expression and/or function of LOX-1 results in the improve-
ment of cellular functions and reduction of atheroscle-
rotic lesion formation, suggesting that LOX-1 might be an
attractive therapeutic target for the management and the
prevention of atherosclerosis.
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